Cystatin C Detection Model
What this model detects
This model governs interpretation of kidney function biomarkers for Vitals coaching — specifically which marker to use, how to zone results, and when to suppress or override wearable-derived eGFR.
Core problem: Apple Watch estimates eGFR using creatinine-based equations via Apple Health. For users on creatine supplementation or GLP-1/retatrutide therapy, creatinine-based eGFR is systematically misleading. Cystatin C-based eGFR (or BIS2 when both markers are available) is the reliable alternative.
What features matter
| Feature | Direction of artifact | Magnitude | Reliability |
|---|---|---|---|
| Serum cystatin C | Direct kidney function signal | — | High — stable production independent of muscle |
| CKD-EPI 2021 cystatin C eGFR | Primary metric when cystatin C only | — | High — P30 87–90% PMID 34554658 |
| BIS2 eGFR (creatinine + cystatin C) | Preferred when both markers available | Misclassification 11.6%; P30 >90% | High — KDIGO 2024 recommended PMID 38490803 |
| Creatinine-based eGFR (standard) | Falsely low in creatine users | −10–30 mL/min | High — well-characterized artifact |
| Creatinine-based eGFR (GLP-1 therapy) | Falsely high from lean mass loss | Variable | High — mechanistic basis confirmed PMID 40630318 |
| Apple Watch eGFR | Falsely low in creatine users; falsely high on GLP-1 | Same magnitude as above | High — same creatinine equation |
| Thyroid (hyperthyroidism) | Falsely elevates cystatin C | Clinically significant | High PMID 12675875 |
| Thyroid (hypothyroidism) | Falsely reduces cystatin C | Clinically significant | High PMID 12675875 |
| Glucocorticoids (≥10 mg/day prednisone eq.) | Falsely elevates cystatin C | +20–50% | High PMID 31352865 |
Certainty limits
High certainty:
- Creatinine-based eGFR (including Apple Watch) is unreliable for creatine users and GLP-1 therapy patients
- Cystatin C is unaffected by creatine supplementation or acute changes in muscle mass
- GLP-1/retatrutide has NO direct effect on cystatin C production or clearance
- Thyroid status must be known before interpreting cystatin C
Moderate certainty:
- BIS2 superiority over CKD-EPI cystatin C alone is most established in older adults (≥70); the margin in young, muscle-mass-changing individuals is smaller but BIS2 remains the safest combined option
- Obesity (Class II–III) elevates cystatin C independently of GFR (OR 2.82) PMID 18374694
Low certainty:
- Cystatin C CV of 6–8% means serial trend detection requires concordant movement across both markers and intervals ≥6 months
Apple Watch eGFR Override Logic
IF user.creatine_supplementation == true:
DISPLAY "⚠️ Apple Watch eGFR is unreliable (creatinine confounded by creatine supplementation)"
SHOW cystatin_C_eGFR or BIS2_eGFR as primary metric
SUPPRESS apple_watch_eGFR from alerts and coaching nudges
ELIF user.GLP1_therapy == true AND user.lean_mass_loss_active == true:
DISPLAY "⚠️ Apple Watch eGFR may be falsely elevated (creatinine suppressed by lean mass loss)"
SHOW cystatin_C_eGFR or BIS2_eGFR as primary metric
SUPPRESS apple_watch_eGFR from alerts and coaching nudges
ELIF user.known_thyroid_dysfunction == true:
DISPLAY "⚠️ Cystatin C may be confounded by thyroid dysfunction"
FLAG for clinical review before interpreting eGFR
ELIF user.glucocorticoid_use == true:
DISPLAY "⚠️ Cystatin C may be falsely elevated by glucocorticoid use"
FLAG for clinical review; consider creatinine-based eGFR as alternative
ELSE:
SHOW apple_watch_eGFR with standard caveat "Creatinine-based estimate; confirm with blood panel if any concern"
Coaching Zone Definitions
⚠️ Human sign-off required for any Red-zone or clinical interpretation. These are evidence-adapted thresholds for Vitals coaching, not clinical practice guidelines.
Reference Ranges (Young Adult Male)
| Marker | Normal | Borderline | Clinical Concern |
|---|---|---|---|
| Cystatin C (mg/L) | <1.0 | 1.0–1.5 | >1.5 |
| eGFR (CKD-EPI CysC or BIS2) | ≥90 mL/min/1.73m² | 60–89 | <60 |
🟢 GREEN — Routine Monitoring
- Cystatin C: <1.0 mg/L
- eGFR: ≥90 mL/min/1.73m²
- Coaching: Continue standard monitoring; retest in 6 months or at next retatrutide follow-up. No immediate action required.
🟡 YELLOW — Increased Monitoring
- Cystatin C: 1.0–1.5 mg/L OR
- eGFR: 60–89 mL/min/1.73m²
- Coaching:
- Increase hydration
- Minimize nephrotoxic exposures (NSAIDs, contrast agents)
- Retest in 4–6 weeks
- If on glucocorticoids or thyroid medication → flag for clinical review before interpreting cystatin C result
- If on GLP-1 therapy → confirm lean mass trajectory and protein intake
🔴 RED — Clinical Review Required
- Cystatin C: >1.5 mg/L OR
- eGFR: <60 mL/min/1.73m²
- Coaching:
- See primary care or nephrologist within 1–2 weeks
- Flag for human clinical review
- Do NOT act on Apple Watch eGFR in this range
- Do not use this result alone for clinical decisions
Monitoring Frequency Algorithm
IF eGFR >= 90 AND cystatin_C < 1.0:
ZONE = "GREEN"
NEXT_TEST = 6_months
COACHING = "Routine monitoring"
ELIF (eGFR 60-89 OR cystatin_C 1.0-1.5) AND NOT (eGFR < 60 OR cystatin_C > 1.5):
ZONE = "YELLOW"
NEXT_TEST = 4-6_weeks (confirmatory retest)
IF retest_confirms:
NEXT_TEST = 3-4_months_ongoing
COACHING = "Hydration + nephrotoxin avoidance + clinical review if confounders present"
ELIF eGFR < 60 OR cystatin_C > 1.5:
ZONE = "RED"
NEXT_TEST = 2_weeks (clinical review)
COACHING = "Human sign-off required; nephrology referral within 1-2 weeks"
TRIGGER (any zone):
acute_illness OR dehydration OR NSAID_use:
NEXT_TEST = 2_weeks_post_event
Lab Integration
Test codes and costs
| Provider | Code | Test | CPT | Self-pay |
|---|---|---|---|---|
| Quest | 94588 | Cystatin C + eGFR | 82610 | ~212 |
| LabCorp | 121265 | Cystatin C + eGFR | 82610 | ~123 |
| LabCorp | 121022 | BIS2 (creatinine + cystatin C eGFR) | — | ~130 |
| DTC (Walk-In Lab, Request-A-Test, Ulta) | — | Cystatin C | 82610 | ~130 |
Preferred: LabCorp 121022 (BIS2) when both markers are available. Quest 94588 or LabCorp 121265 when only cystatin C is ordered.
Fasting: Not required for any cystatin C test.
Relationship to this vault
Parent hub:
- Cystatin C Kidney Monitoring — primary hub; biomarker facts, equations, non-GFR determinants, evidence summary
Companion detection notes:
- Creatinine Artifact — Creatine Supplementation — mechanistic basis for creatinine eGFR artifact; Apple Watch override logic rationale
- Sarcopenia Detection — muscle health detection framework; links cystatin C to sarcopenia monitoring
- Muscle Health Biomarkers — detailed biomarker comparison; Sarcopenia Index formula
Stack context:
- Retatrutide — Ben’s GLP-1 agent; cystatin C eGFR is primary kidney metric
- Creatine — reason creatinine-based eGFR is unreliable for Ben
- GLP-1 Body Composition — lean mass loss context; why creatinine becomes doubly confounded during GLP-1 therapy
- GLP-1 Muscle Preservation — preservation evidence; kidney monitoring is part of muscle health safety
Key PMIDs
| PMID | Topic |
|---|---|
| 34554658 | CKD-EPI 2021 race-free cystatin C equation (NEJM) |
| 38490803 | KDIGO 2024 CKD guideline (BIS2 recommendation) |
| 23027318 | BIS2 equation validation |
| 40630318 | Retatrutide Phase 2: eGFR changes track equivalently across equations |
| 12675875 | Thyroid dysfunction elevates/reduces cystatin C |
| 31352865 | Glucocorticoid elevates cystatin C production |
| 18374694 | Obesity elevates cystatin C (NHANES III, OR 2.82) |